Ritonavir is a protease inhibitor with action adjoin Human Immunodeficiency Virus Type 1 (HIV-1). Protease inhibitors block the allotment of HIV alleged protease. HIV-1 protease is an agitator appropriate for the proteolytic break of the viral polyprotein precursors into the alone anatomic proteins begin in communicable HIV-1. Ritonavir binds to the protease alive website and inhibits the action of the enzyme. This inhibition prevents break of the viral polyproteins consistent in the accumulation of adolescent non-infectious viral particles. Protease inhibitors are about consistently used in aggregate with at atomic two added anti-HIV drugs.
Ritonavir inhibits the HIV viral proteinase agitator which prevents break of the gag-pol polyprotein, consistent in noninfectious, adolescent viral particles.